These data are important for their quality, primacy, and clinical significance. However, as the authors point out, substantial work remains to be done on psychotherapy for depression in Parkinson's disease. The treatment group had much more attention during the study than the control group, so we do not know whether other psychotherapeutic options, such as interpersonal therapy, would work as well. It also remains to be shown what degree of therapist expertise is required for treatment success. However, the results are remarkably good compared to usual clinical care, and they are unlikely to be due to the placebo effect alone. In fact, the treatment group improved substantially more than did Parkinson's disease patients at the authors' own center who took placebo pills in a double-blind randomized controlled trial of antidepressant medications (9). More work will also be needed to clarify how widely these results generalize within the Parkinson's disease population.